Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators. Xu J, et al. Among authors: guo q, guo y. JAMA. 2023 Dec 5;330(21):2064-2074. doi: 10.1001/jama.2023.19918. JAMA. 2023. PMID: 38051328 Free PMC article. Clinical Trial.
Efficacy and safety of sustained-release oxycodone compared with immediate-release morphine for pain titration in cancer patients: A multicenter, open-label, randomized controlled trial (SOCIAL).
Pan H, Shen P, Shu Q, Lu L, Qian S, Zhou Y, Han F, Guo Q, Yang Z, Pan J, Xu Q, Zhang P, Wang K. Pan H, et al. Among authors: guo q. Medicine (Baltimore). 2019 Jun;98(24):e15505. doi: 10.1097/MD.0000000000015505. Medicine (Baltimore). 2019. PMID: 31192908 Free PMC article. Clinical Trial.
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.
Li Z, Jiang W, Zhou H, Cen H, Zhang M, Lv F, Zhang Q, Sun X, Liu L, Huang Y, Yang H, Gao S, He C, Yang W, Li W, Yu D, Yang Y, Cheng Y, Qian Z, Xiang Y, Guo Q, Xu B, Song Y, Zhang L, Lin L, Shen J, Yan F, Liu H, Zhang D, Wang J, Zhou M, Zhu X, Zhang W, Zhao W, Feng R, Zhang X, Jin J, Zhong M, Zhang M, Wang J, Jing H, Wang Z, Zhao H, Zhu J. Li Z, et al. Among authors: guo q. J Immunother Cancer. 2024 Oct 24;12(10):e008895. doi: 10.1136/jitc-2024-008895. J Immunother Cancer. 2024. PMID: 39455094 Free PMC article. Clinical Trial.
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial.
Bi F, Dong J, Jin C, Niu Z, Yang W, He Y, Yu D, Sun M, Wang T, Yin X, Zhang R, Chen K, Wang K, Wang Z, Li W, Zhang Z, Zhang H, Guo Q, Wang X, Han L, Zhang X, Shen W, Zhang L, Ying J, Wu M, Hu W, Li Z, Li X, Feng W, Zhang B, Li L, Kang X, Guo W. Bi F, et al. Among authors: guo q, guo w. J Hematol Oncol. 2024 Nov 11;17(1):109. doi: 10.1186/s13045-024-01627-5. J Hematol Oncol. 2024. PMID: 39529169 Free PMC article. Clinical Trial.
Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study.
Ye P, Cheng Y, Lian J, Tong H, Li L, Guo Q, Zhu W, Feng W, Huang L, Shou L, Chen D, Liu X, Li S, Du X, Yang M, Yu W, Qian J, Hu C, Wang H, Jin Y, Shen J, Hong P, Pei R, Jin J, Lu Y. Ye P, et al. Among authors: guo q. Br J Haematol. 2024 Jun;204(6):2342-2350. doi: 10.1111/bjh.19367. Epub 2024 Feb 23. Br J Haematol. 2024. PMID: 38400570 Clinical Trial.
12,462 results
You have reached the last available page of results. Please see the User Guide for more information.